I just have had the opportunity to present my work at the European sarcoma meeting #EuSARC23 in Viena! It has been a great opportunity to meet the very best experts in the field and receive great feedback from them📋🖊️; I am taking with me a really wonderful experience!😄

A nice evening at the Pediatric Cancer Center Barcelona celebrating 20 years of the Pediatric Cancer laboratory at HSJD Hospital Sant Joan de Déu Barcelona ES

📢The ITCC Scientific Days have kicked off! We are looking forward to the next two days packed with groundbreaking presentations and a programme that includes scientific abstracts covering the most promising directions in the field of #PediatricOncology. #ChildhoodCancer

That's a wrap! The last two days have been incredibly productive and filled with great discussions. Special thanks to St. Anna Children's Cancer Research Institute CCRI, St. Anna Children’s Hospital and MedUni Wien for hosting us in Vienna☀️ Thank you all for joining us - We look forward to the next edition!

Fantastic congress with our new friend from IRB Mònica Sánchez Guixé in beautiful Vienna.

Kicking off a rapid fire round of flash talks, María Sánchez-Jiménez Institut de Recerca Sant Joan de Déu discusses the mechanisms underlying Aurora Kinase B Inhibitors and the vital search for new targeted combination treatment strategies in Ewing sarcoma #AESR

🚨Nosa compañeira, Marta Iglesias Martínez-Almeida, do Grupo Neurociencia Traslacional do IISGaliciaSur, le a súa tese o xoves, 18 de xaneiro. Reserva a data!🚨 🗓️ 18/01/2024 🕛12:00 horas 🏫 Salón de Actos Facultade Bioloxía Universidade de Vigo  👉 i.mtr.cool/ebebmwbomi #IISGS

🏥 L'origen del càncer pediàtric. L'IRB Barcelona i Hospital Sant Joan de Déu Barcelona ES troben patrons de com apareix un segon tumor | Elena Santos 📲 MINUT A MINUT: rtve.es/n/16021361

Our work on the origins of second malignancies in children is out in Cancer Discovery IRB Barcelona bbglab Institut de Recerca Sant Joan de Déu doi.org/10.1158/2159-8… 1/16

Great talk by Pablo Táboas from the lab at the #EuSARC2024 conference on epigenetics of RMS!

Finally here! Dual intOGen and boostDM release is out today! A great team effort 💪 One step closer towards the Automatic Learning Platform for driver discovery🥳👏

🎖🌍 La família de la Cristina ha impulsat una investigació sobre el rabdomiosarcoma que ha estat reconeguda amb un prestigiós premi internacional. sjdhospitalbarcelona.org/ca/collabora/n…

🔬 La Dra. Estela Prada, primera autora de la investigació, ha rebut el Premi Odile Schweisguth, que la Societé Internationale d’Oncologie Pediátrique, atorga cada any al millor investigador en formació oncològica pediàtrica i que s’entrega aquest cap de setmana en el congrés

Estela Prada-Varela received the honourable Schweisguth Prize for her research on “PRKG1 hinders myogenic differentiation and predicts response to AKT inhibitor Ipatasertib in Rhabdomyosarcoma” 👏 #SIOPcongress

Magnífica noticia: la terapia CAR-T ha logrado la remisión completa de un tumor cerebral incurable. España es líder mundial en estas terapias avanzadas con 1.406 pacientes tratados. Gracias a la ciencia se abrirán nuevas vías para muchos más. eldiario.es/sociedad/terap…

Happy to finally share our last work doi.org/10.1002/1878-0… many thanks to everybody involved. Great effort by Roser Lopez Mariona Chicón-Bosch 🧬, Sarcomas IDIBELL and the collaborations of SilviaML and @GrunewaldLab #research #sarcoma #metastasis

Finalment veu la llum!! Tot l’esforç d’anys de feina, experiments i hores del Sarcomas IDIBELL ha tingut recompensa!! Molt contenta d’aquesta feina en equip, sobretot Sara Sánchez-Serra Oscar Martinez Roser Lopez ! Avenços en la investigació de les metàstasis del Sarcoma d’Ewing

Marta M. Alonso galardonada con XIV Premio Nacional de Investigación en Cáncer Doctores Diz Pintado cicancer.org/science-societ…

España alcanza récord histórico mundial: 6.464 trasplantes en 2024. Nuestro modelo es referencia para el mundo, desarrollando técnicas punteras que salvan vidas cuando parecía imposible. Orgullo de la solidaridad de la sociedad, los profesionales y la sanidad pública.